Reducing COVID vaccine hesitancy by inducing a comparative mindset
Vaccine, ISSN: 0264-410X, Vol: 40, Issue: 52, Page: 7547-7558
2022
- 1Citations
- 40Captures
- 5Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations1
- Citation Indexes1
- Captures40
- Readers40
- 40
- Mentions5
- News Mentions5
- 5
Most Recent News
-University of Minnesota: Reduce vaccine hesitancy by focusing on options
Asking people to choose a COVID-19 vaccine rather than asking whether they would get vaccinated can reduce vaccine hesitancy, even across party lines, according to
Article Description
To investigate if a behavioral nudge comprising a vaccination opportunity that employs a comparative probe first (i.e., which vaccine to take) versus the more commonly-used deliberative probe (i.e., willingness to take a vaccine), reduces vaccine hesitancy, while controlling for political partisanship. In a randomized study, conducted on Amazon Mechanical Turk and Prolific, we varied the manner in which the vaccination offer is posed. In one group, participants were asked to compare which vaccine they would like to take (i.e., the comparative probe), while, in another group, participants were asked to deliberate whether they would like to take the vaccine (i.e., the deliberative probe). Participants’ political preferences were also measured. The primary outcome variable was vaccine hesitancy. A LOGIT regression (N = 1736), was conducted to test the research questions. Overall, the comparative probe yielded a 6% reduction in vaccine hesitancy relative to the typical deliberative probe. Additionally, while vaccine hesitancy varies due to individual political views, the comparative probe is effective at reducing vaccine hesitancy even among the most vaccine hesitant population (i.e., Pro-Trump Republicans) by almost 10% on average. Subtly changing the manner in which the vaccination offer is framed, by asking people to compare which vaccine to take, and not deliberate about whether they would like to take a vaccine, can reduce vaccine hesitancy, without being psychologically taxing or curtailing individuals’ freedom to choose. The nudge is especially effective among highly vaccine hesitant populations such as Pro-Trump Republicans. Our results suggest a costless communication protocol in face-to-face interactions on doorsteps, in clinics, in Pro-Trump regions and in the mass media, that might protect 5 million Americans from COVID-19.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0264410X22013597; http://dx.doi.org/10.1016/j.vaccine.2022.10.077; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85142691593&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/36357289; https://linkinghub.elsevier.com/retrieve/pii/S0264410X22013597; https://dx.doi.org/10.1016/j.vaccine.2022.10.077
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know